Accessibility navigation

Technology evaluation: Colostrinin (ReGen)

Rattray, M. (2005) Technology evaluation: Colostrinin (ReGen). Current Opinion in Molecular Therapeutics, 7 (1). pp. 78-84. ISSN 1464-8431

Full text not archived in this repository.

Official URL:


ReGen Therapeutics is developing Colostrinin, a polypeptide complex derived from ovine colostrums, for the potential treatment of Alzheimer's disease. The compound is currently undergoing phase II clinical trials.

Item Type:Article
Divisions:Faculty of Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
No Reading authors. Back catalogue items
ID Code:15727
Uncontrolled Keywords:Alzheimer Disease/*drug therapy Animals Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Colostrum/*chemistry Female Humans PC12 Cells Peptides/*chemistry/metabolism/pharmacokinetics/*therapeutic use Pregnancy Rats

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation